INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events... READ MORE

For US healthcare professionals

Your patients at increased risk of MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) don’t have time to wait for lower LDL-C1

The incidence of clinical ASCVD is on the rise in the United States, with ~2.9 million new cases in 20212,*

watch-icon-two

Every

~40
seconds in the United States:

A patient has an MI3

A patient has a stroke3

Lipid Test Icon
76%
of very high-risk ASCVD patients

did not have a lipid test in the year following their most recent MI4,†

LDL-C Icon
80%
of very high-risk ASCVD patients

treated with low-to-moderate-intensity statin ± ezetimibe did not achieve LDL-C <55 mg/dL4,†

LDL-C Icon
74%
of very high-risk ASCVD patients

treated with high-intensity statin ± ezetimibe did not achieve LDL-C <55 mg/dL4,†

dr-turnbo
If we are not reaching the recommended [LDL-C level] and we have already reached maximum statin therapy, we’ll go ahead and consider an introduction to Repatha®.

– Dr. Turnbo

Act Now. Help patients at increased risk of MACE, with or without a prior heart attack or stroke.5,6

Patients at increased risk of MACE

  • High-Risk Primary Prevention
    (High-Risk Diabetes Without Known ASCVD)

  • Secondary Prevention (With Known ASCVD)

High-risk diabetes with no known ASCVD

High-Risk Factors

  • Uncontrolled LDL-C: above ADA guideline-recommended LDL-C level of 70 mg/dL
  • Age 65
  • Type 2 diabetes diagnosed 10+ years ago (high-risk diabetes)
  • No history of MI or stroke
LDL-C
  • 98 mg/dL
Statin History
  • Maximally
    tolerated dose

Hypothetical Patient

Help patients at high CV risk without prior MI or stroke reduce their risk of MACE (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization).

Add Repatha®

Next Patient Profile
Next Patient Profile

Hypothetical Patient

  • ASCVD RISK FACTORS FROM THE ADA GUIDELINES

    The American Diabetes Association (ADA) considers patients at high risk of ASCVD based on the following:

    Diabetes + ≥1 ASCVD risk factors (aged 40-75)7,8

    ASCVD risk factors include:

Prior CV event(s) + additional CV risk factors

Very High-Risk Factors

  • Prior MI (>12 months)
  • Diabetes
  • Hypertension
LDL-C
  • 160 mg/dL
CAC Score
  • 520 Agatston units (AU)
  • BMI 31
Statin History
  • Maximally tolerated
    dose

Hypothetical Patient

Help patients with a prior CV event reduce their risk of MACE (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization).

Add Repatha®

Previous Patient Profile
Previous Patient Profile

Hypothetical Patient

  • VERY HIGH-RISK DEFINITION

    2018 AHA/ACC/MULTISOCIETY GUIDELINE DEFINITION OF A VERY HIGH-RISK ASCVD PATIENT10

    Heart Icon

    Multiple major ASCVD events

    • Recent ACS (within the past 12 months)
    • History of MI (other than recent ACS event listed above)
    • History of ischemic stroke
    • Symptomatic PAD (claudication with ABI <0.85, or prior revascularization/amputation)
    or
    Risk Icon

    One major ASCVD event and multiple high-risk conditions

    • Age ≥65 years
    • Prior CABG or PCI outside major ASCVD event(s)
    • Diabetes mellitus
    • HeFH
    • CKD (eGFR 15-59 mL/min/1.73 m2)
    • Hypertension
    • Current smoking
    • History of CHF
    • Persistently elevated LDL-C (≥100 mg/dL [≥2.6 mmol/L] despite maximally tolerated statin therapy + ezetimibe)

    94% of patients with a history of major ASCVD events had additional risk factors that placed them in the very high-risk category11,‡

Continuing the commitment to help
patients reach their recommended LDL-C

SEE OUR COMMITMENT TO PATIENTS

See How Repatha® Can Help Your Patients With Known ASCVD Achieve Treatment Goals

play icon

Identifying patients who might be right for Repatha®

Duration: 5:14 minutes

Hear Dr. Shah share her insights and experience treating myocardial infarctions in patients with established CVD. Dr. Shah identifies patients who could benefit from Repatha® to lower LDL-C and the risk of another MI or stroke.

*The data were taken from The Institute for Health Metrics and Evaluation’s Global Burden of Disease Study. The open source data were used to determine the incidence of new clinical ASCVD cases, defined as: ischemic heart disease, stroke, ischemic stroke, and peripheral artery disease.

†Retrospective patient study from IQVIA using an anonymized patient claims data set encompassing nearly 5.4 million patients who experienced Ml and met criteria for VHR ASCVD. Data set from January 1, 2018, to December 31, 2022. 17.1% of patients were treated with low-to-moderate-intensity statin ± ezetimibe, 40.4% high-intensity statin ± ezetimibe, and 44.2% untreated with lipid-lowering therapy. LDL-C levels for this analysis were available for 441,736 VHR ASCVD patients following their most recent MI.

‡A retrospective cohort study of 16,344 patients 19 years of age or older with a history of major ASCVD events using data from the MarketScan database. 5,919 patients had symptomatic PAD as their history of a major ASCVD event. Patients were followed from January 1, 2016 through December 31, 2017 for recurrent ASCVD events. Major ASCVD events included recent ACS, history other than a recent ACS, history of ischemic stroke, and symptomatic PAD.

ACS = acute coronary syndrome; ADA = American Diabetes Association; ASCVD = atherosclerotic cardiovascular disease; BMI = body mass index; CAC = coronary artery calcium; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; IQVIA = IMS Quintiles Virtual Information Access; LDL-C = low-density lipoprotein cholesterol; MACE = major adverse cardiac events; MI = myocardial infarction; PAD = peripheral artery disease; VHR = very high risk.

References: 1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. 2. Data on file, Amgen; 2024. 3. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596. 4. Data on file, Amgen; 2023. 5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418. 6. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357. 7. American Diabetes Association. Standards of medical care in diabetes—2024. Diabetes Care. www.professional.diabetes.org/standards-of-care. Accessed October 28, 2025. 8. American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. ada.silverchair-cdn.com/ada/content_public/journal/care/issue/48/supplement_1/7/standards-of-care-2025.pdf. Accessed October 19, 2025. 9. Repatha® (evolocumab) Prescribing Information, Amgen. 10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285-e350. 11. Muntner P, Orroth KK, Mues KE, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:475-481.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top